发明名称 |
USE OF TACI-IG FUSION PROTEIN SUCH AS ATACICEPT FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING LUPUS ERYTHEMATOSUS |
摘要 |
<p>In various embodiments, the present invention provides methods, compositions, dosing, and administration schedules for treatment of autoimmune diseases, including systemic erythematosus (SLE), for example, comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule such as atacicept. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BLyS and APRIL, in particular the use of multiple administrations of the fusion molecule at relatively low dose over the course of the treatment.</p> |
申请公布号 |
EP2167038(A2) |
申请公布日期 |
2010.03.31 |
申请号 |
EP20080771043 |
申请日期 |
2008.06.13 |
申请人 |
ZYMOGENETICS, INC.;ARES TRADING S.A. |
发明人 |
BUSBY, SHARON J.;GROSS, JANE A.;VISICH, JENNIFER;NESTOROV, IVAN;MUNAFO, ALAIN;PAPASOULIOTIS, ORESTIS;PENA ROSSI, CLAUDIA |
分类号 |
A61K9/06;A61K9/00;A61K38/00 |
主分类号 |
A61K9/06 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|